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RESULTS: The presence of diabetes-related co-morbidities,
notably neuropathy predicted overall TS and 3/5 domains (p <
0.05). Retinopathy impacted Device Satisfaction, age was related
to Lifestyle Flexibility (p < 0.05). No other baseline patient/
disease characteristic impacted TS. Lowered HbA1c impacted
overall TS, and 3/5 domains (p < 0.05). Number of hypoglycemic
events impacted Hypoglycemic Control, timing of the event was
related to overall TS and all domains (p < 0.001). Weight gain,
number of daily injections and treatment group did not impact
TS despite the presence of signiﬁcant treatment group difference.
When all signiﬁcant factors were examined together, HbA1c
reduction and neuropathy maintained their impacts on TS. The
impact of the number of hypoglycemic events remained only for
Hypoglycemic Control, while timing of the hypoglycemic event
impacted overall TS and 3/5 domains (p < 0.01). CONCLU-
SION: Contrary to clinical wisdom, the number of daily injec-
tions may not negatively impact TS when balanced by signiﬁcant
HbA1c treatment beneﬁts. Factors impacting TS when examined
independently did not always exert the same signiﬁcant inﬂuence
when assessed in combination with other factors. Clinicians
should judge the balance between positive and negative treat-
ment outcomes before considering treatment options.
ENDOCRINE DISORDERS
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DETERMINATION OF THE TOTAL COST OF DIAGNOSTIC
PROCEDURE BY FINE NEEDLE ASPIRATION CYTOLOGY IN
PATIENTS WITH THYROID NODULES
Borget I,Vielh P, Schlumberger M, De Pouvourville G
Gustave Roussy Institute,Villejuif, France
OBJECTIVES: The prevalence of thyroid nodules is high with
four to seven percent in the general population. Fine-needle aspi-
ration cytology (FNA-t) is recommended as the reference test
because it is minimally invasive, presents an optimal positive pre-
dictive value and is cost-effective when compared to whole-body-
scan (WBS). The diagnosis is known for the fraction of patients
operated. Suspicious ﬁndings are a dilemma. For benign and
indeterminate results, a long-term follow-up delayed the time of
diagnosis. This study aims to determine the total cost of a true
diagnosis by FNA-t. The model takes account of false-positive,
false-negative, suspicious and indeterminate results.
METHODS: A Markov model was built describing the trajec-
tory and the management of patients, from the ﬁrst FNA-t and
until a conclusive diagnosis was obtained. We derived estimates
for patient, diagnostic accuracy values and follow-up from a ret-
rospective study, including patients who had their ﬁrst FNA-t in
2003 or 2004. Costs were computed from the viewpoint of the
hospital. A microcosting study was assessed to determine the unit
cost of FNA-t. Costs of hospital stays for surgery were extracted
from the hospital cost accounting. Sensitivity analyses were per-
formed. RESULTS: A total of 105/390 patients were operated.
Speciﬁcity and sensitivity values were respectively 86% and
78%. The unit cost of FNA-t was estimated to €118. Markov
modeling showed that the mean total cost of a true diagnosis
was €997 per patient, including unnecessary surgeries, FNA-t
and follow-up. Cost decreased with the capacity of the cytolo-
gist to minimize indeterminate results. CONCLUSION: The true
cost of a given procedure exceeds its unit cost of production.
This result is conditional to the performance of the cytologist
and is highly dependent on the 29% of indeterminate results.
Ultrasound-guidance would reduce this rate and the true cost by
a great deal at a relatively low unit cost.
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OBJECTIVE: To assess the economic impact to the US payer of
recombinant human growth hormone (rHGH) utilization in a
pediatric population. METHODS: rHGH may be administered
to pediatric patients via vial/syringe or pen injection systems pro-
vided by six manufacturers. Variation in annual drug cost is
largely a function of dosing efﬁciency and price per milligram
(mg). A budgetary impact model was developed to calculate drug
costs based on product waste and cost. Waste was calculated as
the difference between prescribed dose, based on patient weight,
and actual delivered dose, based on dosing increments and
maximum deliverable dose for pens and a ﬁxed percent waste as
derived from the literature for vials. Annual drug costs were cal-
culated based upon total mg delivered, using a daily dose of 0.03
mg/kg and wholesale acquisition cost. Total annual drug costs,
assuming equal use of vials and pens from each manufacturer,
were compared for two scenarios: 1) A mix based on national
market share and 2) restricting use to the product with lowest
waste. RESULTS: Based on the literature, waste for each vial
product was 23%, including injection error (15%) and
syringe/needle dead space (8%). Among individual pens, waste
was highest for Humatrope 24 mg (19.5%) and lowest for
Norditropin NordiFlex 5 mg (1.1%). Equal use of vials and pens
from each manufacturer resulted in the following product waste:
Tev-Tropin 23% (vial only), Nutropin 18.4%, Humatrope
14.5%, Genotropin 7.1%, Saizen 4.6%, and Norditropin 3.6%.
Restricting use to the product with least waste (Norditropin)
resulted in an 11.0% reduction in annual patient cost from
$19,196 to $17,089 compared to national share mix. CON-
CLUSION: Pen delivery systems result in less waste than vial and
syringe. Considering all approved delivery systems, Norditropin
resulted in the least product waste and lower annual patient cost.
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OBJECTIVE: To assess the economic impact to the US payer of
recombinant human growth hormone (rHGH) utilization in an
adult population. METHODS: rHGH may be administered to
adults via vial/syringe or pen injection systems provided by six
manufacturers. Variation in annual drug cost is largely a func-
tion of dosing efﬁciency and price per milligram (mg). A bud-
getary impact model was developed to calculate drug costs based
on product waste and cost. Waste was calculated as the differ-
ence between prescribed dose, based on patient weight, and
actual delivered dose, based on dosing increments and maximum
deliverable dose for pens and a ﬁxed percent waste as derived
from the literature for vials. Annual drug costs were calculated
based upon total mg delivered, using a daily dose of 0.016 mg/kg
and wholesale acquisition cost. Total annual drug costs, assum-
ing equal use of vials and pens from each manufacturer, were
compared for two scenarios: 1) A mix based on national market
share and 2) restricting use to the product with lowest waste.
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RESULTS: Based on the literature, waste for each vial product
was 23%, including injection error (15%) and syringe/needle
dead space (8%). Among individual pens, product waste 
was highest for Humatrope 24 mg (14.3%) and lowest for
Norditropin NordiFlex 5 mg (1.0%). Equal use of vials and pens
from each manufacturer resulted in the following product waste:
Tev-Tropin 23% (vial only), Nutropin 18.2%, Humatrope
12.2%, Genotropin 5.5%, Saizen 3.8%, and Norditropin 3.0%.
Restricting use to the product with least waste (Norditropin)
resulted in a 10.5% reduction in annual patient cost from
$24,764 to $22,161 compared to a national share mix. CON-
CLUSION: Pen delivery systems result in less waste than vial and
syringe. Considering all approved delivery systems, Norditropin
resulted in the least product waste and lower annual patient cost.
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Christensen T1, Djuurhus C1,Andersen S2, Kragh N2, Clayton P3,
Christiansen J4
1Novo Nordisk, Bagsvaerd, Denmark, 2University of Southern
Denmark, Odense, Denmark, 3University of Manchester, Manchester,
UK, 4Århus University Hospital, Århus, Denmark
OBJECTIVES: Short stature has been shown to inﬂuence social
factors during childhood and adult life. However, limited data
exist to determine the inﬂuence of short stature on Health
Related Quality Of Life (HRQOL) due to underpowered studies
and the fact that children ﬁnd questionnaires very hard to com-
plete. The objective of this study was to characterize the inﬂu-
ence of height on social class and HRQOL for the general adult
population in UK. METHODS: The Health Survey for England
(HSE03) was commissioned by the Department of Health and
collected data during the period 2003 to 2004. HSE03 consisted
of a random population sample in England. Observations for
14,416 adults (age >18 years) were included in the analysis. The
survey involved a questionnaire-based interview followed by a
nurse visit, where measurements and blood samples were taken.
HRQOL was measured using the EQ-5D questionnaire. Social
class (I-V) were derived according to deﬁnition from UK
National Statistics. Height was converted from centimetres to
height percentiles (0%–100%) to obtain standardized scores.
RESULTS: A regression analysis showed increasing height had a
signiﬁcant inﬂuence on increasing HRQOL. The largest HRQOL
differences were observed in the shorter groups. An ANOVA
showed HRQOL for the shortest 2.5% (EQ-5D = 0.791) was
signiﬁcantly reduced (P = 0.007) compared with all other persons
(EQ-5D = 0.873). The data showed a trend towards increasing
height having an inﬂuence on number of persons in social class
I + II. However, this trend could not account for the relationship
between height and HRQOL in the shorter subgroups. CON-
CLUSIONS: Short stature negatively impacts upon HRQOL and
does this independently of social class. The impact of height on
HRQOL was largest in the shorter height subgroups. Effects of
distinct causes of short stature can not be excluded, however sta-




IS COMBINATION THERAPY OF LAMIVUDINE WITH
INTERFERON-ALPHA SUPERIOR TO LAMIVUDINE
MONOTHERAPY FOR HBEAG-POSITIVE CHRONIC HEPATITIS
B? A META-ANALYSIS OF RANDOMIZED TRIALS
Sun X1, Zhou R2, Li Y1, Zhao L3
1West China Hospital, Sichuan University, Chengdu, China, 2West
China Medical School, Chengdu, China, 3Center of Infectious
Diseases, West China Hospital, Sichuan University, Chengdu, China
OBJECTIVE: Assess comparative efﬁcacy of combination
therapy of interferon-alpha with lamivudine versus lamivudine
monotherapy for HBeAg-positive chronic hepatitis B (CHB).
METHODS: Searched MEDLINE, SCI-Expand, Current
Content Connect, Cochrane Library and Chinese Biomedical
Database to April 25, 2006, and screened reference lists of eli-
gible trials. Randomized trials were included if comparing
lamivudine plus interferon-alpha with lamivudine alone in
patients with HBeAg-positive and ALT-elevated CHB. We
recorded interventional and patient characteristics. Quality of
trials was assessed by six items based on the Cochrane recom-
mendation. We used ﬁxed and random effect model meta-analy-
sis to pool the data. Two types of interventional strategies were
available: a) lamivudine in both arms were administrated 52
weeks; and b) lamivudine was administrated 24 weeks in com-
bination arm while 52 weeks in monotherapy. We stratiﬁed trials
for analysis, and performed sensitivity analysis based on the dose
of interferon-alpha, where appropriate. RESULTS: Twenty ran-
domized trials were included. Quality was moderate in most.
Both at 24-week (for both types) and 52-week (for type b) of
treatment, loss of HBeAg (RR = 2.54 and 1.62, 95%CI =
1.91–3.37; 1.13–2.33, p = 0.000 and 0.009) and HBeAg sero-
conversion (RR = 3.12 and 1.73, 95%CI = 2.07–4.70;
1.20–2.51, p = 0.000 and 0.004) were signiﬁcantly higher in
combination than lamivudine monotherapy. Loss of HBV DNA,
loss of HBsAg and normalization of ALT were not statistically
signiﬁcant. Two strategy types were limited in follow-up data.
However, loss of HBV DNA was signiﬁcantly higher in combi-
nation group after a 26-week follow-up in both strategies; no
signiﬁcant difference was found in serological and biomedical
markers. CONCLUSIONS: It was suggested that combination
therapy might be superior to lamivudine therapy in clearing sero-
logical markers but not for virological and biomedical ones
during treatment. Further study was needed to investigate the
long-term beneﬁt of combination therapy.
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FROM A SYSTEMATIC REVIEW OF RANDOMISED
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OBJECTIVES: To compare the efﬁcacy of esomeprazole with the
European licensed standard dose of PPIs for the endoscopic
healing of reﬂux oesophagitis (i.e. esomeprazole 40 mg compared
with lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40
mg, and rabeprazole 20 mg). METHODS: Systematic review of
CENTRAL, BIOSIS, EMBASE and MEDLINE for randomised
controlled trials (RCTs) in patients with reﬂux oesophagitis was
conducted in February 2005. Data on endoscopically veriﬁed
healing rates at four and eight weeks were extracted and 
